Stay updated on SBRT +/- Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 in the page history. This appears to be a minor site version update with no substantive changes to study data or navigation.SummaryDifference0.0%

- Check21 days agoChange DetectedRevision: v3.4.1 was added to the history and Revision: v3.4.0 was removed.SummaryDifference0.0%

- Check28 days agoChange DetectedGlossary visibility controls and color-coded highlights for additions and deletions were added to the study history page. Revision notes now show 'Revision: v3.4.0', and 'No FEAR Act Data' was removed.SummaryDifference0.2%

- Check42 days agoChange DetectedFooter now shows Revision: v3.3.4, replacing v3.3.3.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision: v3.3.3 was added to the footer, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check70 days agoChange DetectedThe history version now includes new core content sections: Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Arms and Interventions, and Study Status. These updates expand the data on safety, outcomes, and trial design for NCT03924869 (version dated 2025-12-11, preceding version 2025-11-24, entry 167).SummaryDifference0.2%

Stay in the know with updates to SBRT +/- Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in NSCLC Clinical Trial page.